Introduction
============

Proteolytic remodeling of extracellular matrix is an essential event in a variety of physiological processes such as embryonic development, angiogenesis, reproduction, wound healing, and bone formation and remodeling ([@bib55]). On the other hand, abnormal breakdown of connective tissue components contributes to a large number of pathological conditions including rheumatoid arthritis, atherosclerosis, and tumor invasion and metastasis ([@bib35]). A large body of evidence indicates that the matrix metalloproteinases (MMPs)[\*](#fn1){ref-type="fn"} play a central role in all of these tissue-remodeling processes. These enzymes comprise a family of zinc-dependent endopeptidases that are collectively capable of degrading all protein constituents of the extracellular matrix. At present, the family of human MMPs is composed of more than 20 members that according to structural and functional considerations can be classified into six different families: collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other MMPs ([@bib51]). Among all of these proteins, members of the collagenase subgroup are the principal neutral proteases with ability to degrade fibrillar collagens, generating fragments 3/4 and 1/4 the size of the original molecules, which denature rapidly and become susceptible to further degradation by other MMPs. To date, three human collagenases have been identified: fibroblast collagenase (MMP-1), neutrophil collagenase (MMP-8), and the most recently described collagenase-3 (MMP-13) ([@bib16]).

Collagenase-3 represents a good model to study the molecular mechanisms that modulate the expression of MMPs during normal and pathological conditions. This potent metalloprotease is overexpressed in a growing variety of human pathological processes including malignant tumors (for review see [@bib4]), inflammatory conditions ([@bib50]), atherosclerosis ([@bib49]), aortic aneurysms ([@bib33]), and destructive joint diseases such as osteoarthritis and rheumatoid arthritis ([@bib30]). However, in marked contrast with its wide distribution in pathological processes collagenase-3 expression in physiological conditions has only been detected during fetal ossification and postnatal bone remodeling ([@bib48]) and at lower levels in the course of some reproductive processes ([@bib3]; [@bib14]). Recent studies have provided information on the mechanisms controlling collagenase-3 expression in both normal and pathological conditions (for review see [@bib4]). Thus, we and others have reported that Cbfa1, a transcription factor of the *runt* gene family involved in skeletal development, induces the expression of collagenase-3 during bone formation ([@bib22]; [@bib40]; [@bib45]). This gene is also strongly induced by bone-resorbing agents such as parathyroid hormone (PTH) and IL-6 in diverse in vitro systems including osteoblastic cell lines and mouse calvarial osteoblasts ([@bib38]; [@bib28]). We have also described that collagenase-3 is expressed within fibroblasts adjacent to invasive breast cancer cells in response to diffusible factors released from the epithelial tumor cells ([@bib52]). Furthermore, it has been reported that IL-1β and TNF-α may induce collagenase-3 expression in osteoarthritic cartilage ([@bib46]), whereas serotonin may be important in the upregulation of this gene during reproductive processes ([@bib14]). However, a series of factors like PDGF, aFGF, or EGF previously found to play important roles in upregulating expression of other MMPs did not show any effect on collagenase-3 expression by human fibroblasts ([@bib52]; [@bib53]). By contrast, TGF-β assumed to be inhibitory for most MMPs induces collagenase-3 expression in fibroblasts and transformed keratinocytes ([@bib53]; [@bib41]; [@bib23]). Because these findings suggested that the mechanisms regulating collagenase-3 expression could be distinct from those operating in the control of other MMPs, we have tried to extend our search for factors that could act as mediators of collagenase-3 expression in normal and pathological conditions.

All-trans retinoic acid (RA) could be a good candidate to act as an inducer of collagenase-3 expression during bone formation or in pathological processes involving bone-forming cells. In fact, retinoids have been found to play important roles in mammalian embryonic limb development and in bone growth and remodeling during fetal and postnatal life ([@bib19]). However, contrary to this possibility, most previous studies have shown that RA is inhibitory for MMP expression ([@bib29]; [@bib36]; [@bib44]; [@bib43]; [@bib6]). In this work, we provide evidence that collagenase-3 and other MMPs involved in bone formation, such as MT1-MMP ([@bib20]; [@bib57]), are induced by RA and RA derivatives in embryonic cartilage rudiments and chondrocytic cells. We also analyze the morphological effects resulting from the treatment of these cells with RA and correlate the observed effects with altered patterns of gene expression including those of Cbfa1, MMPs, and osteocalcin genes. Finally, we perform an analysis of the molecular mechanisms and signaling pathways mediating collagenase-3 induction by RA with the finding that RA acts through a signaling pathway involving RAR-RXR heterodimers and is mediated by p38 mitogen-activated protein kinase (MAPK). On the basis of the transcriptional regulation studies presented herein, together with morphological and functional observations, we propose that RA induces a regulatory cascade involving Cbfa1 and MMPs and is coupled to the development of a perichondrial invasion and osteogenic differentiation process that occurs during endochondral ossification.

Results
=======

Collagenase-3 and MT1-MMP are induced by retinoic acid in chondrocytic cells
----------------------------------------------------------------------------

To study the putative effect of RA on the expression of collagenase-3 during bone formation, we first performed in situ hybridization experiments on embryonic metatarsal rudiments. As can be seen in [Fig. 1](#fig1){ref-type="fig"}, a and c, relatively low levels of collagenase-3 transcripts were found in cartilage from control samples. Labeling was restricted to some hypertrophic chondrocytes and cells localized in the perichondrium, but it was not detected in proliferating or in resting chondrocytes. By contrast, a high level of collagenase-3 expression was found in rudiments treated with 10^−7^ M RA for 7 d ([Fig. 1, b and d](#fig1){ref-type="fig"}). In these samples, expression of collagenase-3 was located mainly at an abnormally extended perichondrium, being especially marked in those zones in which it seems to invade into the underlying cartilage. In most cases, positive signal was found in spindle-shaped cells having oval nuclei and small size ([Fig. 1](#fig1){ref-type="fig"} d). As in control animals, chondrocytes expressing collagenase-3 were low in number and restricted to the hypertrophic zone. The overexpression of collagenase-3 induced by RA was coupled to a series of morphological alterations in the metatarsal rudiments ([Fig. 1, e and f](#fig1){ref-type="fig"}). Thus, the longitudinal growth was reduced (control length, 3.1 ± 0.18 mm, *n* = 4; treatment with 10^−8^ RA, 2.7 ± 0.17 mm, *n* = 4, *p* \< 0.05; treatment with 10^−7^ RA, 2.2 ± 0.14 mm, *n* = 4, *p* \< 0.01). Histologically, the RA-treated metatarsal rudiments showed a decrease in the degree of structural anisotropy. As a result, boundaries between resting and proliferating zones appeared poorly defined and could hardly be recognized in these samples ([Fig. 1](#fig1){ref-type="fig"} f). Likewise, RA treatment resulted in a partial inhibition of cellular enlargement during chondrocytic hypertrophy. In this way, hypertrophic-like chondrocytes showing mitotic figures were sometimes observed in RA-treated cartilages. Additionally, the perichondrium in RA-treated cultures appeared bigger and more irregular than in controls. Whereas the perichondrium in controls was only two to three layers thick ([Fig. 1](#fig1){ref-type="fig"} e), the perichondrium in RA-treated cultures contained five to nine layers of cells, often invading into the underlying cartilage ([Fig. 1](#fig1){ref-type="fig"} f). Proteoglycan content, as estimated by cytochemical staining with Alcian blue, was lower in RA-treated cartilages. This effect was especially evident in zones where the perichondrium expands and gives rise to cup-shaped depressions protruding into cartilage. An abrupt transition was evident between the weakly Alcian blue--stained intrachondral cells invading from the perichondrium and the strongly stained surrounding chondrocytes ([Fig. 1](#fig1){ref-type="fig"} g). Such intrachondral cells were larger in size than surface perichondrial cells, presented basophilic cytoplasm ([Fig. 1](#fig1){ref-type="fig"} h), and were histochemically positive for calcification (unpublished data). The characteristics of perichondrium-derived cells in RA-treated rudiments partially resembled those of osteoblasts and clearly differed from those of untreated bones where a sequential differentiation process from perichondrial cells to chondrocytes was observed.

![**Collagenase-3 expression in metatarsal bone rudiments.** Paraffin sections from embryonic metatarsal rudiments untreated (a and c) or treated with RA (b and d) were hybridized with a labeled antisense riboprobe for collagenase-3. In untreated cultures, collagenase-3 expression was relatively low, being restricted to a low number of cells located mainly in the perichondrium. (c) Higher magnification of a peripheric area showing that most collagenase-3--positive cells were small sized and flat shaped. Metatarsals treated with RA (b) showed higher levels of collagenase-3 expression. Positive signal was increased in zones in which the perichondrium invaded into the underlying cartilage (d). (e--h) Metatarsal sections untreated (e) and treated with RA (f--h) and stained with toluidine blue (e, f, and h) and Alcian blue (g). A clear boundary between proliferating and hypertrophic zones was observed in untreated metatarsals (e). RA-treated cultures showed a partial inhibition of cellular enlargement during chondrocytic hypertrophy resulting in ill-defined boundaries between proliferating and hypertrophic zones (f). Invasion of cartilage by cells from the perichondrium also increased in RA-treated cultures (f, arrowhead; g and h). Weakly Alcian blue--stained intrachondral cells invading from the perichondrium are observed in g. (h) Higher magnification of intrachondral cells showed in g and stained with toluidine blue. These cells are elongated and have basophilic cytoplasm. Bars: (a, e, and f) 100 μm; (b) 160 μm; (c, d, and g) 40 μm; (h) 25 μm.](0106147f1){#fig1}

To further study the effect of RA on the expression of collagenase-3, we first used primary chondrocyte cultures. Cells were treated with 10^−6^ M RA, and total RNA was obtained at different times and analyzed by Northern blot using a specific collagenase-3 probe. As shown in [Fig. 2](#fig2){ref-type="fig"} a, RA induced the accumulation of a 2.9-kb mRNA transcript corresponding to collagenase-3, the maximal effect being reached between 24 and 48 h and declining at longer times of incubation. Similar results were obtained when rat chondrosarcoma (RCS) cells were used as the experimental model. The main advantage of using this cell line derives from the fact that its chondrocyte phenotype is extremely stable in standard tissue culture conditions compared with the unstable phenotype exhibited by other cells from the same lineage ([@bib34]). RCS cells treated with 10^−6^ M RA also showed a marked induction of collagenase-3 expression ([Fig. 2](#fig2){ref-type="fig"} b). In addition, a dose--response analysis showed that as little as 10^−7^ M RA induced a detectable expression of collagenase-3 mRNA, whereas incubation of the cells with 10^−5^ M induced a maximal accumulation of this mRNA (unpublished data). To determine if the inducing effect of RA on collagenase-3 mRNA levels was also reflected at the protein level, we performed Western blot analysis with conditioned medium from RCS cells treated with RA. As can be seen in [Fig. 2](#fig2){ref-type="fig"} c, a band immunoreactive against collagenase-3 monoclonal antibodies was detected in medium from cells treated with 10^−6^ M RA for 48 h. This band was absent in medium obtained from control untreated cells. A time course analysis demonstrated that the maximum level of collagenase-3 protein was detected in cells treated with RA for 72 h ([Fig. 2](#fig2){ref-type="fig"} c).

![**Effect of RA on expression of collagenase-3 and different chondrocytic and osteoblastic markers.** (a) Primary chondrocytes were exposed to 10^−6^ M RA for the times shown, and then total RNA was extracted and analyzed by Northern blot with collagenase-3 and MT1-MMP cDNA probes. 28S rRNA stained with ethidium bromide is shown as loading control. (b) RCS cells were incubated with 10^−6^ M RA for the times shown, and total RNA was then analyzed as in a. (c) RCS cells were treated with 10^−6^ RA for the times indicated, and proteins in conditioned media were analyzed by Western blot using an antibody against collagenase-3. Cells were also treated for 72 h with different RA concentrations, and collagenase-3 protein secreted to media was detected. Primary chondrocytes (d) or RCS cells (e) were induced with 10^−6^ M RA for the times shown, and total RNA was analyzed by Northern blot with specific probes for the indicated genes.](0106147f2){#fig2}

We next examined the possibility that other MMPs could also be a target of the upregulatory effect of RA in chondrocytic cells. We focused our interest on MT1-MMP, a membrane metalloproteinase essential for bone formation ([@bib20]; [@bib57]) and proposed to be part of a proteolytic cascade involving collagenase-3 ([@bib25]). As illustrated in [Fig. 2](#fig2){ref-type="fig"}, a and b, MT1-MMP expression was increased by RA treatment both in RCS cells and primary chondrocyte cultures, although in these cells the upregulatory effect was lower. Further studies also revealed that other MMPs, such as gelatinase B (MMP-9) potentially involved in bone formation, are not significantly upregulated by retinoids in chondrocytic cells (unpublished data).

Collagenase-3 induction by retinoic acid is coupled to an osteogenic differentiation process mediated by Cbfa1
--------------------------------------------------------------------------------------------------------------

After treatment of cell cultures with RA, a clear time-dependent change in cell morphology was found. Both primary chondrocytes and RCS cells shifted from rounded polygonal shape to a very distinct flattened and more stellate shape, being such changes correlated with a decrease of proteoglycan content (unpublished data). In addition, an increase in calcium deposition was observed in RCS cells and primary cultures of chondrocytes. Previous studies have provided opposing results on the role that RA exerts on chondrocytic differentiation. Some works have shown that RA induces maturation and mineralization of chondrocytes ([@bib21]; [@bib7]; [@bib27]), whereas other groups have reported that RA exerts an inhibitory effect on chondrocyte function ([@bib5]; [@bib11]). To analyze the molecular alterations associated with these morphological changes, we examined the putative occurrence of variations in the expression levels of different genes that could be associated with chondrocytic differentiation. Northern blot analysis revealed that type II collagen expression was strikingly downregulated after RA treatment of primary chondrocytes and RCS cells ([Fig. 2, d and e](#fig2){ref-type="fig"}). The loss of this cartilage-specific collagen suggested that chondrocytic cells had differentiated toward a mature hypertrophic chondrocyte or, alternatively, had dedifferentiated toward a fibroblastic phenotype. Hybridization of the blots with a probe for type X collagen showed the absence of detectable mRNA transcripts of this gene whose expression is characteristic of hypertrophic chondrocytes. However, hybridization of the same blots with probes for osteoblastic markers provided positive results. Thus, type I collagen positive signal was observed in RA-treated primary chondrocytes ([Fig. 2](#fig2){ref-type="fig"} d). Similarly, osteocalcin mRNA was markedly induced in RA-treated RCS cells ([Fig. 2](#fig2){ref-type="fig"} e), although the effect on primary cultures was virtually undetectable (unpublished data). These differences in the expression patterns of both types of RA-treated cells indicate that their response to retinoids is not identical, although they share several common RA-induced morphological and molecular alterations suggestive of their differentiation toward osteoblastic-like cells. In relation to this, it is remarkable the finding that matrix molecules, including osteocalcin, are only expressed in some populations of morphologically indistinguishable osteoblasts depending on variations in maturational status or in the microenvironment in which they are present ([@bib8]). Consistent with this, in situ hybridization experiments on metatarsal rudiments revealed that osteocalcin transcripts were detected clearly in some cells from rudiments treated with 10^−7^ M RA for 7 d ([Fig. 3](#fig3){ref-type="fig"} a) but not in control samples. In these RA-treated rudiments, expression of osteocalcin significantly overlapped that of collagenase-3, being found in a relatively low number of small spindle-shaped cells located in zones where the perichondrium appeared to protrude into the underlying cartilage ([Fig. 3](#fig3){ref-type="fig"} a). Osteocalcin expression was negatively correlated with proteoglycan content ([Fig. 3](#fig3){ref-type="fig"} b).

![**Osteocalcin and Cbfa1 expression in metatarsal bone rudiments treated with RA.** Osteocalcin mRNA was found in RA-treated rudiments in a low number of cells located in zones in which perichondrium appeared extended into the underlying cartilage (a). Cells showing positive signal (arrowhead) were small sized and spindle shaped and partially overlapped those positive for collagenase-3. Osteocalcin expression was correlated with a decrease of proteoglycans as demonstrated by cytochemical detection with Alcian blue on paraffin sections (b, arrowhead). Cbfa1 expression was observed in both untreated rudiments (c) and treated with RA (d). In untreated cultures, Cbfa1 expression was low, being restricted to cells of the perichondrium (arrowhead) and some hypertrophic chondrocytes (asterisk). By contrast, metatarsals treated with RA (d) showed higher levels of Cbfa1 expression that partially overlapped that of collagenase-3. Positive signal was especially evident in central (diaphyseal) zones in which the perichondrium was expanded and typical chondrocytes were scarce (arrowhead). Bars: (a and b) 250 μm; (c and d) 67 μm.](0106147f3){#fig3}

We next tried to evaluate the possibility that the effect of RA could be mediated by protein factors involved in bone cells maturation. In this regard, it is remarkable that Cbfa1, a transcription factor involved in the maturation of chondrocytes and osteoblasts, is an in vivo inducer of both osteocalcin and collagenase-3 expression in bone cells ([@bib13]; [@bib22]; [@bib40]; [@bib45]). From these considerations, we examined the possibility that RA could modulate Cbfa1 levels in RCS cells and primary cultures of chondrocytes. Interestingly, and as shown in [Fig. 2, d and e](#fig2){ref-type="fig"}, Northern blot analysis confirmed that RA induced the expression of this transcription factor. Cbfa1 induction was detected at 24 h of RA treatment, thus preceding the appearance of collagenase-3 transcripts. Cbfa1 transcripts overlapping with those of collagenase-3 were also increased in RA-treated metatarsal rudiments ([Fig. 3, c and d](#fig3){ref-type="fig"}).

To further support the possibility that the effect of RA on collagenase-3 expression was mediated by Cbfa1, we performed metatarsal organ cultures from embryos with targeted deletion of the Cbfa1 gene. A comparative morphological analysis with control littermate metatarsal rudiments revealed that Cbfa1-null rudiments were shorter in both total length (3.0 ± 0.11 mm, *n* = 4 versus 3.7 ± 0.14 mm, *n* = 5, *p* \< 0.01) and fraction of hypertrophic cartilage. RA treatment of rudiments from Cbfa1^−/−^ mice resulted in a slight decrease of longitudinal growth (2.7 ± 0.12 mm, *n* = 4 versus 3.0 ± 0.11 mm, *n* = 4, *p* \< 0.01) that was proportionally lower than that observed in RA-treated Cbfa1^+/+^ rudiments (2.8 ± 0.14 mm, *n* = 5 versus 3.7 ± 0.14 mm, *n* = 5, *p* \< 0.01). RA treatment of Cbfa1^−/−^ rudiments also resulted in a marked inhibition of chondrocytic hypertrophy ([Fig. 4](#fig4){ref-type="fig"}, a and c), a result similar to that observed in wild-type samples ([Fig. 1](#fig1){ref-type="fig"}). However, RA treatment did not induce any increase of perichondrial thickness in Cbfa1-null metatarsal rudiments, a result different from that observed in the wild-type samples. In situ hybridization studies showed that collagenase-3 expression was absent in both untreated and RA-treated Cbfa1^−/−^ metatarsal bone rudiments ([Fig. 4, b and d](#fig4){ref-type="fig"}), which agrees with the proposal that Cbfa1 is required for the RA-induced increase of collagenase-3 expression. We next examined the possibility that the effect of RA on collagenase-3 expression could be influenced by the absence of MT1-MMP, which as mentioned above is involved in both bone formation and collagenase-3 activation. To this end, we used metatarsal cultures from MT1-MMP--null embryos and analyzed the effects of RA on these explants. Similar to the case of Cbfa1-null rudiments, MT1-MMP^−/−^ rudiments were shorter than wild-type littermate samples (2.8 ± 0.13 mm, *n* = 6, versus 3.5 ± 0.16 mm, *n* = 4, *p* \< 0.01) and showed a clear histological alteration at the hypertrophic zone where chondrocytes were smaller in size and appeared highly disorganized ([Fig. 4](#fig4){ref-type="fig"} e). RA treatment of MT1-MMP^−/−^ rudiments induced a significant decrease in length (2.1 ± 0.18 mm, *n* = 6 versus 2.8 ± 0.13 mm, *n* = 6, *p* \< 0.01), which was comparable to that observed in wild-type rudiments (2.9 ± 0.13 mm, *n* = 4 versus 3.5 ± 0.16 mm, *n* = 4, *p* \< 0.01). The observed cytological alterations in untreated MT1-MMP^−/−^ samples were also enhanced in RA-treated rudiments ([Fig. 4](#fig4){ref-type="fig"} g). In situ hybridization studies showed positive collagenase-3 expression in both untreated and RA-treated MT1-MMP^−/−^ metatarsi ([Figs. 4, f and h](#fig4){ref-type="fig"}). In untreated rudiments, labeling was restricted to some hypertrophic chondrocytes and cells of the perichondrium, a pattern similar to that observed in samples from control mice ([Fig. 4](#fig4){ref-type="fig"} f). Likewise, RA-treatment of MT1-MMP^−/−^ rudiments resulted in an increased expression of collagenase-3. However, in these mutant bone rudiments collagenase-3 expression was found mainly at the disorganized hypertrophic chondrocytes located at the middle of the bone ([Fig. 4](#fig4){ref-type="fig"} h). Like in Cbfa1^−/−^ metatarsi, RA treatment did not induce any perichondrial expansion in MT1-MMP^−/−^ rudiments. According to these results, we conclude that the RA-induced increase of collagenase-3 expression was not dependent of MT1-MMP.

![**Collagenase-3 expression in metatarsal bone rudiments from embryos with targeted deletion of the Cbfa1 and MT1-MMP genes.** Cbfa1-null (a--d) and MT1-MMP--null (e--h) metatarsal rudiments were untreated (a, b, e, and f) or treated with RA (c, d, g, and h) and stained with Alcian blue and nuclear fast red (a, c, e, and g) or hybridized with a labeled antisense riboprobe for collagenase-3 (b, d, f, and h). Untreated Cbfa1^−/−^ rudiments showed signs of cellular disorganization, especially in the hypertrophic zone where a clear Alcian blue staining was observed (a). Treatment of Cbfa1^−/−^ metatarsi with RA resulted in a marked inhibition of the chondrocytic hypertrophy (c). In situ hybridization studies failed to find positive signal for collagenase-3 in either untreated (b) or RA-treated (d) rudiments. Untreated MT1-MMP^−/−^ rudiments showed a disorganized hypertrophic zone with an intense Alcian blue staining (e). Collagenase-3 expression was low but could be observed in cells located mainly in the perichondrium (f). Treatment of MT1-MMP^−/−^ metatarsi with RA induced some cytological changes (g) and resulted in an increased collagenase-3 expression (h) at the hypertrophic chondrocytes. Bars, 200 μm.](0106147f4){#fig4}

Induction of collagenase-3 expression in chondrocytic cells is mediated by RAR-RXR heterodimers and involves the p38 MAPK pathway
---------------------------------------------------------------------------------------------------------------------------------

The above observation that all-trans RA upregulated collagenase-3 expression in chondrocytic cells prompted us to examine the nature of the nuclear retinoic acid receptors presumably involved in this process. To this purpose, we first analyzed by Northern blot the expression levels of the different retinoid receptors in RCS cells ([Fig. 5](#fig5){ref-type="fig"}). This analysis revealed that RARα and RARγ receptors are constitutively expressed but show some variations after RA treatment, indicating that both of them could be involved in the process. We next evaluated the effect of different agonistic and antagonistic retinoids on collagenase-3 expression in these cells. As shown in [Fig. 6](#fig6){ref-type="fig"} a, the RARα-selective agonist Ro40-6055 induced a collagenase-3 expression similar to that observed with all-trans RA. In addition, when cells were incubated with the RARβ-selective (Ro48-2249) or the RARγ-selective (R044-4753) retinoids, collagenase-3 expression was also induced, although the upregulatory effect was much lower than that observed after treatment with RARα agonists. Furthermore, the RARα-selective antagonist Ro41-5253 extensively blocked the RA-induced accumulation of collagenase-3, whereas the RARβ-selective antagonist LE135 only showed a slight inhibitory effect ([Fig. 6](#fig6){ref-type="fig"} b). Finally, we examined the possibility that RXR-mediated signaling pathways could also contribute to the observed upregulation of collagenase-3 expression by retinoids. Thus, RCS cells were incubated with different RAR agonists in the presence or absence of the RXR-selective retinoid LG100064, and collagenase-3 levels were analyzed by Northern blot. As shown in [Fig. 6](#fig6){ref-type="fig"} a, the presence of this RXR-selective retinoid produced a significant increase in the collagenase-3 mRNA levels when compared with values obtained after incubation with RAR agonists alone. Taken together, these results indicate that RAR-RXR heterodimers, likely containing RARα isoforms, are involved in the transduction of the retinoid signal that leads to the induction of collagenase-3 in chondrocytic cells.

![**Expression of RA receptors in RCS cells.** Cells were induced with 10^−6^ M RA for the times indicated, and total RNA was analyzed by Northern blot with specific probes for αRAR and γRAR.](0106147f5){#fig5}

![**Effect of different RA receptors agonists and antagonists on collagenase-3 expression.** RCS cells were cultured for 48 h in the presence of 10^−6^ M of different agonists (Ro40-6055, αRAR agonist; Ro48-2249, βRAR agonist; Ro44-4753, γRAR agonist; RXR agonist, LG100064) (a) or with 10^−6^ M RA plus different antagonists (Ro41-5253, αRAR antagonist; LE135, βRAR antagonist) (b). Total RNA was extracted, and collagenase-3 transcripts were detected by Northern blot.](0106147f6){#fig6}

To provide further insights into the mechanisms underlying the upregulating effect of RA on collagenase-3 expression in chondrocytic cells, we performed cell culture experiments in the presence of the protein synthesis inhibitor cycloheximide. As shown in [Fig. 7](#fig7){ref-type="fig"} a, incubation of RCS cells with cycloheximide blocked the effect of RA on collagenase-3 mRNA levels. Therefore, we conclude that de novo protein synthesis is required for collagenase-3 induction by RA. We next evaluated the possibility that different signaling pathways could be involved in this process. To this purpose, RCS cells were first incubated with RA in the presence or absence of several inhibitors of these signaling pathways, and the levels of collagenase-3 were examined by Northern blot. As illustrated in [Fig. 7](#fig7){ref-type="fig"} b, the highly specific PKC inhibitor GF109203X diminished the upregulating effect of RA on collagenase-3 expression, indicating the involvement of a PKC in this process. However, the classical but less specific PKC inhibitor staurosporine not only was unable to diminish its expression but even enhanced it, likely through an alternative mechanism ([@bib47]). To determine whether a tyrosine kinase was also involved in collagenase-3 induction, RCS cells were incubated with RA in the presence or absence of genistein. As shown in [Fig. 7](#fig7){ref-type="fig"} b, this inhibitor blocked the induction of collagenase-3 expression elicited by RA. By contrast, incubation of RCS cells with H89, a protein kinase A inhibitor, or with indomethacin, which blocks prostaglandin synthesis, did not diminish RA-mediated induction of collagenase-3 and even promoted it ([Fig. 7](#fig7){ref-type="fig"} b). Taken together, these results indicate that the positive effect of RA on collagenase-3 expression in RCS cells is exerted through a signaling pathway involving PKC and tyrosine kinase activities.

![**Analysis of the signaling pathways involved in RA-mediated induction of collagenase-3 expression.** (a) Effect of cycloheximide (CHX) (0.5 μg/ml) on collagenase-3 mRNA levels induced in RCS cells treated with 10^−6^ M RA for 48 h. (b) Effect of inhibitors of different intracellular signaling pathways on RA-induced collagenase-3 mRNA levels in RCS cells. Genistein (100 μg/ml), staurosporine (2 nM), GF109203X (5 μM), H89 (500 nM), and indomethacin (5 μM) were added to the culture medium 1 h before induction with 10^−6^ M RA. Total RNA was extracted after 48 h and analyzed by Northern blot with a collagenase-3 probe.](0106147f7){#fig7}

On the other hand, it is well established that activation of tyrosine kinase-dependent signaling can activate downstream signaling cascades including MAPKs. To elucidate the putative implication of extracellular signal--regulated kinase (ERK)1,2, Jun NH~2~-terminal kinase (JNK)1, and p38 MAPKs pathways in mediating the RA-dependent induction of collagenase-3 expression in RCS cells, we studied the activation of these different kinases after RA treatment. As illustrated in [Fig. 8](#fig8){ref-type="fig"} a, only p38 showed constitutive levels of activation and was appreciably activated after a 90-min RA treatment. This effect continued for at least 12 h. To test the implication of p38 in RA-elicited collagenase-3 induction, we pretreated RCS cells with the p38 inhibitor SB 203580 and then analyzed the obtained RNA after incubation with RA. As shown in [Fig. 8](#fig8){ref-type="fig"} b, treatment of these cells with SB 203580 abolished the RA-induced expression of collagenase-3. In contrast, the ERK1,2 pathway inhibitor PD 98059 strongly augmented collagenase-3 induction by RA in RCS cells. It is remarkable that PD 98059 alone, in the absence of RA, did not elicit any inductive effect on collagenase-3 expression. We also examined if the actions of these MAPK inhibitors could be extended to other RA-induced genes such as Cbfa1 and osteocalcin. As shown in [Fig. 8](#fig8){ref-type="fig"} b, the p38 inhibitor SB 203580 abolished the RA-induced expression of Cbfa1 and osteocalcin, whereas PD 98059 increased the RA-mediated induction of both genes. These results provide evidence that the p38 MAPK signaling pathway seems essential for expression of the different genes induced by RA in chondrocytic cells, whereas ERK1,2 MAPKs play an inhibitory role on the process.

![**Implication of p38 MAPK in collagenase-3 induction by RA.** (a) RCS cells were treated with 10^−6^ M RA for the times indicated. Cells were lysed, and protein extracts were analyzed by Western blot. The levels of activated ERK1/2, JNK1/2, and p38 were determined using phosphospecific antibodies for the corresponding MAPKs (p-ERK1/2, p-JNK1/2, p-p38). As controls, levels of total ERK1/2 and p38 were determined with specific antibodies. Cell lysates from HaCaT cells treated for 20 min with 10^−7^ M TPA or 20 ng/ml TNF-α were used as positive controls for activated ERK1/2 or JNK1/2 and p38, respectively. (b) Increasing amounts of p38 inhibitor SB 203580 or ERK1/2 inhibitor PD 98059 (μg/μl) were added to the culture medium 1 h before inducing RCS cells with 10^−6^ M RA. Total RNA was extracted, and collagenase-3 transcripts were detected by Northern blot. The same filter was subsequently hybridized with probes specific for Cbfa1 and osteocalcin.](0106147f8){#fig8}

Discussion
==========

Skeletal formation and remodeling are strictly regulated both temporally and spatially by a variety of molecules. Among these regulatory factors, retinoids have raised large interest due to their pleiotropic and profound effects in several events occurring during bone formation. Thus, RA has been implicated in limb bud development, anterior/posterior axis orientation, chondrogenesis, growth plate maturation, chondrocyte apoptosis, and matrix mineralization ([@bib19]). This wide variety of RA functional roles has made difficult to identify the effector molecules involved in these different processes and to elucidate the molecular mechanisms underlying each of them. In this work, we provide evidence that collagenase-3, a potent proteolytic enzyme associated with tumor and arthritic processes but whose expression in normal tissues is essentially restricted to bone formation, is induced by RA in chondrocytes during endochondral ossification. Likewise, MT1-MMP, a membrane-bound protease whose relevance in skeletal formation has been uncovered recently ([@bib20]; [@bib57]), is also induced by RA in chondrocytic cells. Interestingly, the production of these MMPs is concomitant with the development of an RA-induced osteogenic differentiation program mediated by Cbfa1. Finally, we demonstrate that these effects require the participation of a signaling pathway involving the activity of p38 MAPK.

According to in situ hybridization, Northern blot, and Western blot analysis, RA is a potent inducer of collagenase-3 expression in cartilage rudiment cultures, primary chondrocyte cultures, and chondrosarcoma cells. This effect is time and dose dependent, requires protein synthesis, and is mediated by RAR-RXR heterodimers, likely involving RARα isoforms. The finding of an upregulatory effect of RA on the production of proteolytic enzymes like MT1-MMP and collagenase-3 confirms and extends previous observations indicating that different MMPs can be induced by retinoids in human, murine, and avian cells ([@bib5]; [@bib10];[@bib54]; [@bib18]; [@bib37]). However, these findings are in clear contrast with many studies demonstrating that retinoids are repressors of MMP expression ([@bib29]; [@bib36]; [@bib44]; [@bib43]; [@bib6]). These RA-induced inhibitory mechanisms have been proposed to be mediated mainly through interaction of RAR-RXR heterodimers with AP-1 transcription factors, which bind to the AP-1 site present in the promoter region of most MMP genes. Therefore, it is paradoxical that the collagenase-3 gene, which contains a functional AP-1 site ([@bib39]), is not repressed by RA. Some studies have reported that AP-1 sites may also mediate RA stimulatory effects ([@bib12]); however, we have been unable to find any indication of the involvement of the AP-1 site in the RA-induced expression of the collagenase-3 gene as assessed by lack of JNK activation, induction of *fos* or *jun* genes, augmented translocation of these factors to the nucleus, or enhanced binding to the AP-1 element (unpublished data). These results indicate that sequences other than AP-1 influence the responsiveness of the collagenase-3 gene to RA. Therefore, we can conclude that regulation of MMP gene expression by retinoids is complex and markedly dependent on cell type or on available factors mediating RA effects in different normal or pathological conditions.

Previous works have reported conflicting results regarding the role of retinoids in the process of chondrocyte maturation. Thus, several studies have proposed a central role for RA in skeletal development, promoting chondrocyte terminal maturation and matrix mineralization ([@bib21]; [@bib7]; [@bib27]). By contrast, other groups have reported that RA negatively regulates bone growth by inhibiting chondrocyte maturation and bone matrix synthesis ([@bib5]; [@bib11]). Our results derived from morphological studies and gene expression analysis using murine cartilage rudiments and chondrocytic cells support the possibility that RA is a signaling molecule that in cell cultures promotes an osteogenic differentiation program. This effect is attenuated in metatarsal rudiments in which RA induces the invasion of perichondrial osteogenic cells from the perichondrium into the cartilage rudiment. Consistent with previous studies ([@bib5]), RA treatment of murine chondrocytic cells induced morphological changes, resulting in more elongated and flattened cells with stellate-like shape resembling osteoblasts. Furthermore, the coordinated expression of markers such as Cbfa1, osteocalcin, MT1-MMP, and collagenase-3 may reflect defined stages of this differentiation process. Interestingly, RA-treatment of metatarsi from MT1-MMP^−/−^ mice induced collagenase-3 expression in hypertrophic-like chondrocytes but did not lead to formation of collagenase-3--positive cells with osteoblastic characteristics, suggesting that the presence of both proteases is needed for the development of this osteogenic differentiation process. Finally, the observation that RA induces the formation of a mineralized bone matrix also suggests that chondrocytes have acquired some functional capabilities necessary to act as osteoblast-like cells. Nevertheless, we must consider the possibility that the addition of relatively high concentrations of RA may lead to a series of phenotypic changes that do not reflect a true osteogenic differentiation of hypertrophic chondrocytes. However, it is remarkable that concentrations as low as 10^−8^ M RA, which fall within physiological levels ([@bib17]), still have an upregulatory effect on MMP expression in metatarsal rudiments. Therefore, it is tempting to speculate that endogenous retinoids may trigger the regulatory cascade described in this work, leading to induction of MT1-MMP and collagenase-3 that in turn may play a direct role in replacement of cartilage by bone during development.

The induction of MMPs by RA is a transient event. The lag between the initiation of treatment and the expression of MMPs together with the observation that the effect of RA on collagenase-3 production is dependent of de novo synthesis of proteins indicate that the induction of an intermediate factor may be involved in this process. An interesting possibility is that Cbfa1, a key regulator of osteoblast differentiation and function ([@bib24]), may act as this intermediate factor. Several experimental findings provide support to this proposal. Thus, we have shown that Cbfa1 expression in RCS cells is also strongly upregulated by RA in a time-dependent manner. We have also found that Cbfa1 is necessary for collagenase-3 expression as assessed by the lack of expression of this gene in both untreated and RA-treated metatarsal rudiments obtained from Cbfa1-null mice. Furthermore, recent in vivo and in vitro studies have demonstrated that Cbfa1 is essential for controlling transcriptional activation of genes encoding osteoblastic proteins through binding to Cbfa functional elements present in these genes ([@bib13]; [@bib22]). Finally, we have also observed the presence of putative Cbfa elements in the MT1-MMP promoter, which is also induced by RA in these cells ([Fig. 2](#fig2){ref-type="fig"}; unpublished data). Assuming that this differentiation process triggered by RA is mediated by Cbfa1 and leads to the induction of MMPs, we can speculate about the potential role of these proteolytic enzymes during bone development. Thus, the wide substrate specificity of collagenase-3 could facilitate the degradation of different matrix components of the bone anlagen in order to initiate the formation of mature bone. In addition, collagenase-3 in collaboration with other MMPs ([@bib15]) may regulate the availability of bone growth factors sequestered as inactive molecules in the matrix or blocked by interaction with their binding proteins. Finally, collagenase-3 could facilitate the matrix invasive processes occurring after cartilage calcification in a manner similar to that proposed for MMPs during tumor invasion ([@bib32]). On the other hand, the importance of MT1-MMP for bone formation seems clear if we consider that mice deficient in this protease exhibit severe skeletal abnormalities that lead to the early death of these mutant animals ([@bib20]; [@bib57]). It has been proposed that inadequate collagen turnover and defects in angiogenesis underlie the observed phenotype, although the possibility that impaired collagenase-3 activation could be responsible at least in part of the observed phenotype cannot be ruled out. Nevertheless, and contrary to the case of Cbfa1, MT1-MMP is not necessary for the observed RA-induced expression of collagenase-3 during bone formation as assessed by the presence of collagenase-3 transcripts in chondrocytes from metatarsal rudiments obtained from MT1-MMP--null mice.

In this work, we have also analyzed the signaling pathways mediating the effect of RA on MMP expression in chondrocytic cells. By using a series of specific inhibitors for different signaling pathways, we have found that the RA action on collagenase-3 is mediated by PKC and tyrosine kinase signal transduction pathways. The finding that a specific PKC inhibitor is effective in blocking the RA stimulatory process on collagenase-3 provides a functional link between PKC and retinoid pathways, which are generally considered to have antagonistic activities on different processes. On the other hand, the observation that induction of collagenase-3 is also dependent on tyrosine kinase activity agrees with previous findings, indicating that these kinases play an essential role in signaling pathways regulating the proteolytic activity of diverse cells ([@bib42]; [@bib56]). Interestingly, we have found that two different MAPK pathways mediate opposite effects on collagenase-3 expression. In fact, inhibition of the ERK1,2 pathway results in collagenase-3 induction, indicating that these MAPKs generate an inhibitory rather than an activating signal on the production of this protease. By contrast, inhibition of the p38 MAPK pathway extensively abolishes the RA stimulatory effect on collagenase-3 expression. Similar results were obtained in the analysis of the effect of both MAPK inhibitors on Cbfa1 and osteocalcin expression. Therefore, it is likely that the balance between p38 and ERK1,2 MAPK pathways will finally determine if these genes are expressed or not. Identification of p38 MAPK as an essential signaling pathway in the induction of Cbfa1, osteocalcin, and collagenase-3 suggests that this pathway might be important during osteogenic differentiation processes. It is also of interest that p38 MAPK has been proposed to play a crucial role in the invasive phenotype of transformed keratinocytes ([@bib23]). The finding that collagenase-3 expression is suppressed by p38 MAPK inhibitors in bone-forming cells supports the proposal that this protease may facilitate some of the invasive processes that take place during bone formation and remodeling.

A final consideration makes reference to the potential relevance of the present results in the context of the therapeutic use of retinoids in several pathological conditions ([@bib31]). Retinoids have been proven to be effective in treating hyperproliferative and inflammatory diseases, skin pathologies, and cancer. Because it is generally accepted that retinoids inhibit MMPs, it was anticipated that these enzymes, which play important roles in these pathologies, could be efficiently targeted by retinoid-based treatments. However, the finding that these compounds have a paradoxical effect on other MMPs like collagenase-3 and MT1-MMP may represent a limitation for the therapeutic use of retinoids in those pathological conditions, including malignant tumors, with ability to produce these proteases. The design and synthesis of novel dissociating retinoids, which are devoid of transactivation properties ([@bib9]), could allow an efficient treatment of these diseases without the undesired properties derived from the induction of factors such as MMPs.

Materials and methods
=====================

Materials
---------

All media and supplements for cell culture were obtained from GIBCO BRL. All-trans RA was from Sigma-Aldrich. Ro40-6055, Ro40-6973, Ro41-5253, Ro46-5471, Ro48-2249, Ro44-4753, and Ro40-8757 were from F. Hoffmann-La Roche Ltd. RXR-retinoid LG100064 was a gift from Dr. U. Reichert (Galderma, Valbonne, France). TNF-α, TPA, cycloheximide, staurosporine, genistein, and indomethacin were from Sigma-Aldrich. H-89 was from Calbiochem.

DNA probes
----------

The collagenase-3 probe was a 2.1-kbp fragment generated by RT-PCR from mouse embryo RNA and corresponding to cDNA positions 334--2,473 (sequence data available from GenBank/EMBL/DDBJ under accession no. [X66473](X66473)). The MT1-MMP probe was a 640-bp PCR fragment from positions 1,060--1,700 in the human cDNA sequence (sequence data available from GenBank/EMBL/DDBJ under accession no. [D26512](D26512)). The gelatinase A probe was a 2.8-kbp EcoRI fragment containing the full-length cDNA for mouse gelatinase A (sequence data available from GenBank/EMBL/DDBJ under accession no. [M84324](M84324)). Type II collagen probe was a 550-bp PstI fragment cloned in PGEM 3Zf vector kindly provided by Dr. Y. Yamada (National Institute of Dental and Craniofacial Research, Bethesda, MD). Type X collagen probe was a 650-bp HindIII fragment of the mouse type X collagen gene ([@bib2]). Cbfa1 probe was a 1.7-kbp EcoRI fragment from plasmid pCMV-Osf2/Cbfa1 ([@bib13]) kindly provided by Dr. G. Karsenty (M.D. Anderson Cancer Center, Houston, TX). Osteocalcin probe was a 209-bp fragment generated by RT-PCR from mouse embryo RNA and corresponding to cDNA positions 59--267 (sequence data available from GenBank/EMBL/DDBJ under accession no. [X04142](X04142)).

Embryonic metatarsal rudiment organ cultures
--------------------------------------------

The three central metatarsal rudiments were isolated from 15.5-d-postcoitum wild-type, Cbfa1^−/−^, and MT1-MMP^−/−^ mouse embryos. The generation of Cbfa1 and MT1-MMP--deficient mice has been described previously ([@bib26]; [@bib20]). Isolated rudiments were cultured in 1 ml of medium containing MEM (GIBCO BRL) supplemented with 0.05 mg/ml ascorbic acid, 0.3 mg/ml [l]{.smallcaps}-glutamine, 0.05 mg/ml gentamicin, 1 mM glycerophosphate, and 0.2% BSA. Explants were grown at 37°C in a humidified 5% CO~2~ incubator. Retinoids were added to cultures 12--14 h after dissection. Medium was changed on the third day of culture. Metatarsal length was calculated at 24 h, 3 d, and 7 d of treatment by using a Nikon microscope equipped with a micrometric eyepiece. Data are shown as the mean ± SD. For statistical analysis, data were compared among the different groups using a one-way analysis of variance followed by Student-Newman *t* test. Metatarsal rudiments were fixed overnight at 4°C in fresh 4% paraformaldehyde and then processed according to two different protocols. Half of them were dehydrated with a graded series of acetone and embedded in Durkupan-ACM (Sigma-Aldrich). 1-μm-thick sections were obtained on a Reicher Ultracut E ultramicrotome and stained with toluidine blue for structural studies and with von Kossa staining for mineralization. The remaining metatarsal rudiments were decalcified in 1 mM Tris, pH 7.5, and 10% EDTA at 4°C for 2 h, dehydrated in ethanol, and embedded in paraffin. 5-μm-thick sections were used for cytochemical detection of proteoglycans and for in situ hybridization.

Cell culture
------------

Primary chondrocytes were isolated from ribs of newborn rats. Rib cages were dissected, and the cartilage parts were cut and placed in DME supplemented with 10% FCS. They were incubated with 0.05 mg proteinase K for 30 min at 37°C, washed, and treated with 1.5 mg collagenase (Type IA; Sigma-Aldrich) for 3 h at 37°C. Chondrocytes were recovered by centrifugation, filtered through a 150 μm mesh, and plated onto Petri dishes. Cells were maintained for 3--7 d in DME supplemented with insulin-transferrin-selenium (Sigma-Aldrich) and thereafter treated with RA for 1--7 d in the same medium also containing 0.05 mg/ml ascorbic acid, 0.3 mg/ml [l]{.smallcaps}-glutamine, 0.05 mg/ml gentamicin, and 1 mM glycerophosphate. RCS cells were provided by Dr. J.H. Kimura (Henry Ford Hospital, Detroit, MI). Cells were maintained routinely in DME supplemented with 10% FCS and 100 μg/ml gentamicin. To test the effect of retinoids, cells were plated and allowed to adhere for 24 h in DME containing 10% FCS. Afterwards, the serum concentration was reduced to 2%, and retinoids were added at different concentrations. Media were changed every 2 d.

Cytochemistry
-------------

Mineralization was detected by von Kossa staining. After fixation in 4% paraformaldehyde in PBS for 30 min, cells were treated with 1% AgNO~3~ for 60 min at room temperature and fixed with 5% sodium hyposulfite. Proteoglycan deposition in cell cultures was analyzed by Alcian blue staining.

In situ hybridization
---------------------

Experiments were basically performed as reported previously ([@bib1]). Hybridization with collagenase-3, Cbfa1, and osteocalcin probes was performed at 58°C for 16 h in a humid chamber with 400 ng/ml of DIG-labeled probe diluted in the same solution used for prehybridization. Parallel sections were hybridized with a labeled sense riboprobe and used as negative controls.

Northern blot analysis
----------------------

Cells were treated with retinoids or different agonists at the concentrations and for the times indicated. Before RNA extraction, cells were pretreated with 1 mg/ml hyaluronidase and 0.15 mg/ml trypsin-EDTA for 2 min at room temperature. Total RNA isolated from the cells was separated by electrophoresis in 1% agarose gels, blotted onto nylon membranes, and hybridized as described previously ([@bib22]).

Western blot analysis
---------------------

Conditioned media were obtained after incubation of cells with the corresponding agents. Proteins from conditioned media were precipitated in 5% trichloroacetic acid, separated by SDS-PAGE, and transferred to nitrocellulose membranes. For detection of collagenase-3, membranes were incubated with a 1:5,000 dilution of monoclonal antibody 141-15A12 (Fuji Chemicals), washed, and then incubated with a goat anti--mouse IgG antisera conjugated to HRP. Finally, the membranes were washed and developed with an HRP chemiluminescence detection reagent (ECL system; Amersham Pharmacia Biotech).

Determination of MAPK activation
--------------------------------

Cells treated with the corresponding agonists were lysed in sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 50 mM DTT, and 0.1% bromophenol blue), heated at 95°C for 10 min, fractionated in 10% SDS-PAGE, and transferred to nylon membranes. Immunodetection of JNK/stress-activated protein kinase, ERK 1,2, and p38 MAPK was performed as described by the antibody supplier (New England Biolabs, Inc.) and developed with the ECL system.
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